Edition:
United Kingdom

NanoString Technologies Inc (NSTG.OQ)

NSTG.OQ on NASDAQ Stock Exchange Global Market

20.98USD
3:36pm GMT
Change (% chg)

$0.13 (+0.62%)
Prev Close
$20.85
Open
$20.56
Day's High
$21.09
Day's Low
$20.56
Volume
10,077
Avg. Vol
79,327
52-wk High
$21.98
52-wk Low
$5.87

Latest Key Developments (Source: Significant Developments)

Nanostring Technologies Sees Q4 2018 Revenue About $30 Million
Monday, 7 Jan 2019 

Jan 6 (Reuters) - NanoString Technologies Inc ::NANOSTRING TECHNOLOGIES PROVIDES PRELIMINARY OPERATIONAL AND FINANCIAL RESULTS FOR FOURTH QUARTER AND FISCAL YEAR 2018.SEES FY 2018 REVENUE $106 MILLION TO $107 MILLION.SEES Q4 2018 REVENUE ABOUT $30 MILLION.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED MORE THAN $90 MILLION AS OF DECEMBER 31, 2018.NANOSTRING TECHNOLOGIES - FOR Q4 OF 2018, PRODUCT AND SERVICE REVENUE EXPECTED ABOUT $23.5 MILLION, EXCEEDING UPPER END OF GUIDANCE RANGE OF $22 TO $23 MILLION.NANOSTRING TECHNOLOGIES - PRODUCT AND SERVICE REVENUE FOR FY 2018 IS EXPECTED ABOUT $83.5 MILLION, EXCEEDING UPPER END OF GUIDANCE RANGE OF $82 TO $83 MILLION.  Full Article

NanoString Technologies - Entered Amended & Restated Loan & Security Agreement That Amends Jan 5 Agreement-SEC Filing
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - NanoString Technologies Inc ::NANOSTRING TECHNOLOGIES - ENTERED AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THAT AMENDS JAN 5 AGREEMENT - SEC FILING.NANOSTRING TECHNOLOGIES - AGREEMENT INCREASES SIZE OF REVOLVING LOAN FACILITY TO $20.0 MILLION AND INCLUDE ELIGIBLE INVENTORY.NANOSTRING TECHNOLOGIES INC - SVB AGREEMENT MATURES ON NOVEMBER 16, 2021.  Full Article

NanoString Technologies Says Enters Translational Research Collaboration With MacroGenics To Identify And Develop Biomarkers In Immuno-Oncology
Monday, 29 Oct 2018 

Oct 29 (Reuters) - MacroGenics Inc ::MACROGENICS AND NANOSTRING ENTER TRANSLATIONAL RESEARCH COLLABORATION TO IDENTIFY AND DEVELOP BIOMARKERS IN IMMUNO-ONCOLOGY.NANOSTRING TECHNOLOGIES INC - CO, MACROGENICS ENTERED AGREEMENT TO IDENTIFY AND DEVELOP BIOMARKERS FOR MACROGENICS' MGD013 PROGRAM.NANOSTRING TECHNOLOGIES INC - WILL DEVELOP, EVALUATE TUMOR INFLAMMATION SIGNATURE AND NOVEL PREDICTIVE GENE EXPRESSION SIGNATURES FOR MGD013.  Full Article

Nanostring Technologies Reports Q2 Loss Per Share Of $0.80
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - NanoString Technologies Inc ::NANOSTRING TECHNOLOGIES RELEASES OPERATING RESULTS FOR SECOND QUARTER OF 2018.Q2 LOSS PER SHARE $0.80.SEES FY 2018 LOSS PER SHARE $2.50 TO $2.70.SEES FY 2018 REVENUE $104 MILLION TO $106 MILLION.NANOSTRING TECHNOLOGIES SEES FISCAL 2018 TOTAL PRODUCT & SERVICE REVENUE OF $79 MILLION TO $81 MILLION.SEES FISCAL 2018 TOTAL REVENUE OF $104 MILLION TO $106 MILLION.NANOSTRING TECHNOLOGIES QTRLY TOTAL PRODUCT & SERVICE REVENUE OF $20.4 MILLION, 11% YOY GROWTH.  Full Article

Nanostring Technologies Announces Pricing Of Public Offering Of 4 Mln Shares Of Common Stock
Tuesday, 17 Jul 2018 

July 17 (Reuters) - NanoString Technologies Inc ::NANOSTRING TECHNOLOGIES ANNOUNCES PRICING OF PUBLIC OFFERING OF 4,000,000 SHARES OF COMMON STOCK.SAYS PUBLIC OFFERING OF 4.00 MILLION COMMON SHARES PRICED AT $12.50PER SHARE.  Full Article

Nanostring Technologies Sees Product And Service Revenue For Q2 Of 2018 $20.4 Mln
Monday, 16 Jul 2018 

July 16 (Reuters) - NanoString Technologies Inc ::NANOSTRING TECHNOLOGIES PROVIDES PRELIMINARY REVENUE RESULTS FOR SECOND QUARTER 2018.SEES PRODUCT AND SERVICE REVENUE FOR Q2 OF 2018 $20.4 MILLION.SEES Q2 COLLABORATION REVENUE IS EXPECTED TO BE APPROXIMATELY $4.5 MILLION.Q2 REVENUE VIEW $25.0 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Nanostring Appoints Thomas Bailey As CFO
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Nanostring Technologies Inc ::NANOSTRING APPOINTS THOMAS BAILEY AS CHIEF FINANCIAL OFFICER.NANOSTRING TECHNOLOGIES INC - THOMAS BAILEY HAS BEEN APPOINTED CHIEF FINANCIAL OFFICER, EFFECTIVE JANUARY 16, 2018.  Full Article

NanoString Technologies cuts 30 jobs; sees FY 2017 revenue between $113 mln-$115 mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Nanostring Technologies Inc ::NANOSTRING TECHNOLOGIES SAYS ‍PRODUCT AND SERVICE REVENUE FOR FISCAL YEAR 2017 IS EXPECTED TO BE ABOUT $72 MILLION, VERSUS PRIOR GUIDANCE OF $68 TO $71 MILLION​.SEES FY 2017 REVENUE $113 MILLION TO $115 MILLION.NANOSTRING TECHNOLOGIES PROVIDES PRELIMINARY OPERATIONAL AND FINANCIAL RESULTS FOR FOURTH QUARTER AND FISCAL YEAR 2017.‍PRODUCT AND SERVICE REVENUE FOR Q4 OF 2017 IS EXPECTED TO BE APPROXIMATELY $21 MILLION​.‍DURING Q4, COMPANY ELIMINATED APPROXIMATELY 30 POSITIONS IN LOWER-PRIORITY AREAS OF BUSINESS​.‍NOW EXPECTS THAT ITS EXISTING CASH ON-HAND WILL BE SUFFICIENT TO FUND ITS OPERATIONS THROUGH MID-2019​.  Full Article

NanoString And RikenGenesis Announce Partnership To Commercialize Ncounter-Based Diagnostic Assays In Japan
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Nanostring Technologies Inc ::NANOSTRING AND RIKENGENESIS ANNOUNCE PARTNERSHIP TO COMMERCIALIZE NCOUNTER-BASED DIAGNOSTIC ASSAYS IN JAPAN.NANOSTRING -‍ UNDER AGREEMENT, CO, RIKEN GENESIS TO COLLABORATE TO REGISTER, OBTAIN REIMBURSEMENT, COMMERCIALIZE COMPANION DIAGNOSTIC ASSAYS IN JAPAN​.  Full Article

Nanostring Technologies reports Q3 loss per share $0.45
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Nanostring Technologies Inc :Nanostring Technologies Inc releases operating results for third quarter of 2017.Q3 loss per share $0.45.Q3 revenue rose 13 percent to $27 million.Sees fy 2017 loss per share $1.86 to $1.99.Nanostring Technologies Inc - sees ‍fy total revenue in range of $109 million to $112 million​.Nanostring Technologies Inc - sees fy ‍gross margin on product and service revenue of approximately 56%​.  Full Article